Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time.

Literature DB >> 32226623

Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time.

Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-reading-udompap a video presentation of this article http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-interview-udompap an interview with the author.

Entities: Gene Species

Year: 2020 PMID： 32226623 PMCID： PMC7098665 DOI： 10.1002/cld.904

Source DB: PubMed Journal: Clin Liver Dis (Hoboken) ISSN： 2046-2484

15 in total

1. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors: Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal: JAMA Date: 2006-01-04 Impact factor: 56.272

2. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Authors: George V Papatheodoridis; Ramazan Idilman; George N Dalekos; Maria Buti; Heng Chi; Florian van Boemmel; Jose Luis Calleja; Vana Sypsa; John Goulis; Spilios Manolakopoulos; Alessandro Loglio; Spyros Siakavellas; Onur Keskın; Nikolaos Gatselis; Bettina E Hansen; Maria Lehretz; Juan de la Revilla; Savvoula Savvidou; Anastasia Kourikou; Ioannis Vlachogiannakos; Kostantinos Galanis; Cihan Yurdaydin; Thomas Berg; Massimo Colombo; Rafael Esteban; Harry L A Janssen; Pietro Lampertico
Journal: Hepatology Date: 2017-10-11 Impact factor: 17.425

3. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.

Authors: Ju-Yeon Cho; Yong-Han Paik; Won Sohn; Hyun Chin Cho; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal: Gut Date: 2014-03-10 Impact factor: 23.059

4. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal: Lancet Date: 2012-12-10 Impact factor: 79.321

5. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.

Authors: Jung Hee Kim; Dong Hyun Sinn; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal: Hepatology Date: 2016-12-24 Impact factor: 17.425

Review 6. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis.

Authors: Siddharth Singh; Larissa L Fujii; Mohammad Hassan Murad; Zhen Wang; Sumeet K Asrani; Richard L Ehman; Patrick S Kamath; Jayant A Talwalkar
Journal: Clin Gastroenterol Hepatol Date: 2013-08-15 Impact factor: 11.382

Review 7. Mechanisms of HBV-related hepatocarcinogenesis.

Authors: Christine Neuveut; Yu Wei; Marie Annick Buendia
Journal: J Hepatol Date: 2010-01-07 Impact factor: 25.083

8. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

Authors: M-F Yuen; H-J Yuan; D K-H Wong; J C-H Yuen; W-M Wong; A O-O Chan; B C-Y Wong; K-C Lai; C-L Lai
Journal: Gut Date: 2005-05-04 Impact factor: 23.059

9. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.

Authors: Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Yee-Kit Tse; Terry Cheuk-Fung Yip; Kelvin Long-Yan Lam; Grace Chung-Yan Lui; Vincent Wai-Sun Wong
Journal: J Hepatol Date: 2018-10 Impact factor: 25.083

10. Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors: Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245

3 in total

1. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.

Authors: Darren Jun Hao Tan; Cheng Han Ng; Phoebe Wen Lin Tay; Nicholas Syn; Mark D Muthiah; Wen Hui Lim; Ansel Shao Pin Tang; Kai En Lim; Grace En Hui Lim; Nobuharu Tamaki; Beom Kyung Kim; Margaret Li Peng Teng; James Fung; Rohit Loomba; Mindie H Nguyen; Daniel Q Huang
Journal: JAMA Netw Open Date: 2022-06-01

Review 2. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?

Authors: Arshi Khanam; Paul G Saleeb; Shyam Kottilil
Journal: Cells Date: 2021-05-04 Impact factor: 6.600

Review 3. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B.

Authors: Yashasavi Sachar; Mayur Brahmania; Renumathy Dhanasekaran; Stephen E Congly
Journal: Viruses Date: 2021-07-08 Impact factor: 5.048

3 in total